We always thought vasopressin did it all. That one hormone handled the body’s thirst. Kept us from drying out. Concentrated our urine.
It wasn’t.
Mayo Clinic nephrologist Fouad Chebib, M.D., found another way. The study appeared in the Journal of Clinical Investigation. It shows kidneys have a backup plan. A pathway for regulating water. It works completely independent of vasopressin.
Chebib called it fundamental.
“It’s not every day,” he said. “That you uncover a new way it carries that function out.”
Hidden Paths In Old Science
This finding adds layers. Decades of physiology textbooks get a rewrite. Or at least an update.
It matters for people with polycystic kidney disease. Fluid-filled cysts grow on the kidneys here. Genetic disorder. Painful. Leads to failure over time.
About 140,00 people in the U.S. have the most common type, ADPKD. Millions globally. Many end up on dialysis. Or needing a transplant.
The Drug That Didn’t Break It
Chebib’s team uses lab-grown cells to watch cysts grow. They wanted to see what made it worse.
They picked compounds they expected to fuel the fire.
One was probenecid.
Old school. 1940s origin story. Introduced to save penicillin supplies during scarce times by keeping the antibiotic from leaking into urine.
“We thought this drug would make it worse,” Chebib admits.
Instead?
It slowed cyst growth.
They repeated it. Same result.
And again.
Urate: The Surprise Signal
So why did probenecid work?
They dug deeper. Found it alters how cells handle urate. You probably know urate as the gout molecule. Not really. In these cells it signals water movement.
Inside the cell, urate triggers an event. It moves water channels to the surface. Kidneys reabsorb water. Urine gets concentrated.
Without vasopressin helping.
“This is a distinct pathway,” Chebib notes. “Different from traditional physiology models.”
The kidney had an extra lever. Pulling it saved water.
Fixing Tolvaptan’s Worst Side Effect
Here is the problem with current treatment.
The only approved drug to slow PKD is tolvaptan. It blocks vasopressin. Cysts grow slower.
But.
Patients pee six or seven liters a day.
Every night. All night.
Many stop taking the drug because it’s exhausting. Impossible to manage.
Chebib’s team added probenecid in preclinical studies and small trials.
Results?
Urine volume dropped. Nighttime bathroom runs dropped.
Patients saw a 30% reduction in urine volume on average. Some went from waking up repeatedly to once. Quality of life improved.
“The goal,” Chebib says. “Is to keep the therapy working but drop the burden.”
Not The Final Answer
Probenecid is not the cure.
It’s ancient medicine. Messy. Hits too many systems. Not even easy to buy anymore.
Chebib wants a cleaner tool. A drug that targets just this new urate pathway. Specifically designed. No side effects. Just water control.
“Probenecid was the key to unlock the door,” he said.
He knows this.
Because his father had PKD.
A personal mission turned into data. Now it’s a new target for therapy.
Maybe this helps someone stay on their meds.
Maybe it keeps a kidney alive a bit longer.
We’ll see.
